Abstract
Lymphedema is a chronic disease with significant morbidity to many patients. Regenerative medicine, cell therapies in particular, has the potential to repair broken physiologic processes and restore health. Vascular regeneration of small vessels is particularly well suited to cellular therapies. This is important because the standard treatment of lymphedema has been frustrated by limited symptom relief, leading many patients to be managed but not cured. Recently, specific molecular mediators have been identified that can be targeted pharmacologically, and it is now known that lymphedema can be reversed, even in the setting of long-standing and/or severe disease. Cell therapies hold promise therapeutically because they can correct deranged pathways in a multi-modal fashion, and this may provide sustained (and possibly complete) regeneration through the recruitment of native reparative cells. This chapter outlines the current symptom-management strategies, the contemporary role of operative therapies in this patient population, and then summarizes existing regenerative medicine approaches being developed to treat lymphedema.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kornuta JA, Nepiyushchikh Z, Gasheva OY, Mukherjee A, Zawieja DC, Dixon JB. Effects of dynamic shear and transmural pressure on wall shear stress sensitivity in collecting lymphatic vessels. Am J Physiol Regul Integr Comp Physiol. 2015;309(9):R1122–34.
Mukherjee A, Hooks J, Nepiyushchikh Z, Dixon JB. Entrainment of lymphatic contraction to oscillatory flow. Sci Rep. 2019;9(1):5840.
Singh AP, Foley J, Tandon A, Phadke D, Karimi Kinyamu H, Archer TK. A role for BRG1 in the regulation of genes required for development of the lymphatic system. Oncotarget. 2017;8(33):54925–38.
Alders M, Al-Gazali L, Cordeiro I, et al. Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome. Hum Genet. 2014;133(9):1161–7.
Pujol F, Hodgson T, Martinez-Corral I, et al. Dachsous1-Fat4 signaling controls endothelial cell polarization during lymphatic valve morphogenesis-brief report. Arterioscler Thromb Vasc Biol. 2017;37(9):1732–5.
Jung M, Cordes S, Zou J, et al. GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cells. Blood Adv. 2018;2(23):3553–65.
DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15.
Executive C. The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology. 2016;49(4):170–84.
Kim SI, Lim MC, Lee JS, et al. Impact of lower limb lymphedema on quality of life in gynecologic cancer survivors after pelvic lymph node dissection. Eur J Obstet Gynecol Reprod Biol. 2015;192:31–6.
Cromwell KD, Chiang YJ, Armer J, et al. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl). 2015;24(5):724–33.
Rockson SG. Lymphedema. Vasc Med. 2016;21(1):77–81.
Armer JM, Stewart BR. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol. 2005;3(4):208–17.
Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008;112(12):2809–19.
Desai SS, Shao M. Vascular outcomes C. Superior clinical, quality of life, functional, and health economic outcomes with pneumatic compression therapy for lymphedema. Ann Vasc Surg. 2019;63:298.
Son A, O'Donnell TF Jr, Izhakoff J, Gaebler JA, Niecko T, Iafrati MA. Lymphedema-associated comorbidities and treatment gap. J Vasc Surg Venous Lymphat Disord. 2019;7(5):724–30.
Miller TA. A surgical approach to lymphedema. Am J Surg. 1977;134(2):191–5.
Charles RH. The surgical treatment of elephantiasis. Ind Med Gaz. 1901;36(3):84–99.
Kobayashi MR, Miller TA. Lymphedema. Clin Plast Surg. 1987;14(2):303–13.
Mavili ME, Naldoken S, Safak T. Modified Charles operation for primary fibrosclerotic lymphedema. Lymphology. 1994;27(1):14–20.
Campisi C. Use of autologous interposition vein graft in management of lymphedema: preliminary experimental and clinical observations. Lymphology. 1991;24(2):71–6.
Chang DW. Lymphaticovenular bypass for lymphedema management in breast cancer patients: a prospective study. Plast Reconstr Surg. 2010;126(3):752–8.
Ho LC, Lai MF, Kennedy PJ. Micro-lymphatic bypass in the treatment of obstructive lymphoedema of the arm: case report of a new technique. Br J Plast Surg. 1983;36(3):350–7.
Koshima I, Inagawa K, Urushibara K, Moriguchi T. Supermicrosurgical lymphaticovenular anastomosis for the treatment of lymphedema in the upper extremities. J Reconstr Microsurg. 2000;16(6):437–42.
Chang DW, Suami H, Skoracki R. A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema. Plast Reconstr Surg. 2013;132(5):1305–14.
Raju A, Chang DW. Vascularized lymph node transfer for treatment of lymphedema: a comprehensive literature review. Ann Surg. 2015;261(5):1013–23.
Cheng MH, Chen SC, Henry SL, Tan BK, Lin MC, Huang JJ. Vascularized groin lymph node flap transfer for postmastectomy upper limb lymphedema: flap anatomy, recipient sites, and outcomes. Plast Reconstr Surg. 2013;131(6):1286–98.
Lin CH, Ali R, Chen SC, et al. Vascularized groin lymph node transfer using the wrist as a recipient site for management of postmastectomy upper extremity lymphedema. Plast Reconstr Surg. 2009;123(4):1265–75.
Gianesini S, Obi A, Onida S, et al. Global guidelines trends and controversies in lower limb venous and lymphatic disease: narrative literature revision and experts' opinions following the vWINter international meeting in phlebology, lymphology & aesthetics, 23-25 January 2019. Phlebology. 2019;34(1 Suppl):4–66.
Patel KM, Lin CY, Cheng MH. A prospective evaluation of lymphedema-specific quality-of-life outcomes following vascularized lymph node transfer. Ann Surg Oncol. 2015;22(7):2424–30.
Pons G, Masia J, Loschi P, Nardulli ML, Duch J. A case of donor-site lymphoedema after lymph node-superficial circumflex iliac artery perforator flap transfer. J Plast Reconstr Aesthet Surg. 2014;67(1):119–23.
Viitanen TP, Maki MT, Seppanen MP, Suominen EA, Saaristo AM. Donor-site lymphatic function after microvascular lymph node transfer. Plast Reconstr Surg. 2012;130(6):1246–53.
Dayan JH, Dayan E, Kagen A, et al. The use of magnetic resonance angiography in vascularized groin lymph node transfer: an anatomic study. J Reconstr Microsurg. 2014;30(1):41–5.
Carl HM, Walia G, Bello R, et al. Systematic review of the surgical treatment of extremity lymphedema. J Reconstr Microsurg. 2017;33(6):412–25.
Pappalardo M, Chang DW, Masia J, Koshima I, Cheng MH. Summary of hands-on supermicrosurgery course and live surgeries at 8th world symposium for lymphedema surgery. J Surg Oncol. 2019;121:8.
Rauniyar K, Jha SK, Jeltsch M. Biology of vascular endothelial growth factor C in the morphogenesis of lymphatic vessels. Front Bioeng Biotechnol. 2018;6:7.
Iwata Y, Fujimoto Y, Morino T, et al. Effects of stem cell mobilization by granulocyte colony-stimulating factor on endothelial function after sirolimus-eluting stent implantation: a double-blind, randomized, placebo-controlled clinical trial. Am Heart J. 2013;165(3):408–14.
Sun Y, Lu B, Deng J, et al. IL-7 enhances the differentiation of adipose-derived stem cells toward lymphatic endothelial cells through AKT signaling. Cell Biol Int. 2019;43(4):394–401.
Lee CY, Kang JY, Lim S, Ham O, Chang W, Jang DH. Hypoxic conditioned medium from mesenchymal stem cells promotes lymphangiogenesis by regulation of mitochondrial-related proteins. Stem Cell Res Ther. 2016;7:38.
Dartsch N, Schulte D, Hagerling R, Kiefer F, Vestweber D. Fusing VE-cadherin to alpha-catenin impairs fetal liver hematopoiesis and lymph but not blood vessel formation. Mol Cell Biol. 2014;34(9):1634–48.
Deng J, Dai T, Sun Y, et al. Overexpression of Prox1 induces the differentiation of human adipose-derived stem cells into lymphatic endothelial-like cells in vitro. Cell Reprogram. 2017;19(1):54–63.
Rockson SG. Lymphatic medicine: paradoxically and unnecessarily ignored. Lymphat Res Biol. 2017;15(4):315–6.
Chen CE, Chiang NJ, Perng CK, Ma H, Lin CH. Review of preclinical and clinical studies of using cell-based therapy for secondary lymphedema. J Surg Oncol. 2019;121:109.
Tian W, Rockson SG, Jiang X, et al. Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci Transl Med. 2017;9(389):eaal3920.
Strassburg S, Torio-Padron N, Finkenzeller G, Frankenschmidt A, Stark GB. Adipose-derived stem cells support lymphangiogenic parameters in vitro. J Cell Biochem. 2016;117(11):2620–9.
Wang S, Yamakawa M, Santosa SM, et al. Quantification of angiogenesis and lymphangiogenesis in the dual ex vivo aortic and thoracic duct assay. Protein Pept Lett. 2019;27:30.
Yan A, Avraham T, Zampell JC, Haviv YS, Weitman E, Mehrara BJ. Adipose-derived stem cells promote lymphangiogenesis in response to VEGF-C stimulation or TGF-beta1 inhibition. Future Oncol. 2011;7(12):1457–73.
Conrad C, Niess H, Huss R, et al. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation. 2009;119(2):281–9.
Takeda K, Sowa Y, Nishino K, Itoh K, Fushiki S. Adipose-derived stem cells promote proliferation, migration, and tube formation of lymphatic endothelial cells in vitro by secreting lymphangiogenic factors. Ann Plast Surg. 2015;74(6):728–36.
Saijo H, Suzuki K, Yoshimoto H, Imamura Y, Yamashita S, Tanaka K. Paracrine effects of adipose-derived stem cells promote lymphangiogenesis in irradiated lymphatic endothelial cells. Plast Reconstr Surg. 2019;143(6):1189e–200e.
Ackermann M, Wettstein R, Senaldi C, et al. Impact of platelet rich plasma and adipose stem cells on lymphangiogenesis in a murine tail lymphedema model. Microvasc Res. 2015;102:78–85.
Hayashida K, Yoshida S, Yoshimoto H, et al. Adipose-derived stem cells and vascularized lymph node transfers successfully treat Mouse Hindlimb secondary lymphedema by early reconnection of the lymphatic system and lymphangiogenesis. Plast Reconstr Surg. 2017;139(3):639–51.
Yoshida S, Hamuy R, Hamada Y, Yoshimoto H, Hirano A, Akita S. Adipose-derived stem cell transplantation for therapeutic lymphangiogenesis in a mouse secondary lymphedema model. Regen Med. 2015;10(5):549–62.
Hwang JH, Kim IG, Lee JY, et al. Therapeutic lymphangiogenesis using stem cell and VEGF-C hydrogel. Biomaterials. 2011;32(19):4415–23.
Shimizu Y, Shibata R, Shintani S, Ishii M, Murohara T. Therapeutic lymphangiogenesis with implantation of adipose-derived regenerative cells. J Am Heart Assoc. 2012;1(4):e000877.
Zhou H, Wang M, Hou C, Jin X, Wu X. Exogenous VEGF-C augments the efficacy of therapeutic lymphangiogenesis induced by allogenic bone marrow stromal cells in a rabbit model of limb secondary lymphedema. Jpn J Clin Oncol. 2011;41(7):841–6.
Gousopoulos E, Proulx ST, Bachmann SB, et al. Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function. JCI Insight. 2016;1(16):e89081.
Robinson ST, Douglas AM, Chadid T, et al. A novel platelet lysate hydrogel for endothelial cell and mesenchymal stem cell-directed neovascularization. Acta Biomater. 2016;36:86–98.
Beerens M, Aranguren XL, Hendrickx B, et al. Multipotent adult progenitor cells support lymphatic regeneration at multiple anatomical levels during wound healing and lymphedema. Sci Rep. 2018;8(1):3852.
Tashiro K, Feng J, Wu SH, et al. Pathological changes of adipose tissue in secondary lymphoedema. Br J Dermatol. 2017;177(1):158–67.
Kondo K, Shintani S, Shibata R, et al. Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29(1):61–6.
Levi B, Glotzbach JP, Sorkin M, et al. Molecular analysis and differentiation capacity of adipose-derived stem cells from lymphedema tissue. Plast Reconstr Surg. 2013;132(3):580–9.
Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia. Circ J. 2012;76(7):1750–60.
Chadid T, Morris A, Surowiec A, et al. Reversible secretome and signaling defects in diabetic mesenchymal stem cells from peripheral arterial disease patients. J Vasc Surg. 2018;68(6S):137S–151S e132.
Morris AD, Dalal S, Li H, Brewster LP. Human diabetic mesenchymal stem cells from peripheral arterial disease patients promote angiogenesis through unique secretome signatures. Surgery. 2018;163(4):870–6.
Rockson SG, Tian W, Jiang X, et al. Pilot studies demonstrate the potential benefits of antiinflammatory therapy in human lymphedema. JCI Insight. 2018;3(20):e123775.
Powell RJ, Marston WA, Berceli SA, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther. 2012;20(6):1280–6.
Forte AJ, Boczar D, Huayllani MT, Cinotto GJ, McLaughlin S. Targeted therapies in surgical treatment of lymphedema: a systematic review. Cureus. 2019;11(8):e5397.
Ismail AM, Abdou SM, Abdelnaby AY, Hamdy MA, El Saka AA, Gawaly A. Stem cell therapy using bone marrow-derived mononuclear cells in treatment of lower limb lymphedema: a randomized controlled clinical trial. Lymphat Res Biol. 2018;16(3):270–7.
Toyserkani NM, Jensen CH, Sheikh SP, Sorensen JA. Cell-assisted Lipotransfer using autologous adipose-derived stromal cells for alleviation of breast cancer-related lymphedema. Stem Cells Transl Med. 2016;5(7):857–9.
Toyserkani NM, Jensen CH, Tabatabaeifar S, et al. Adipose-derived regenerative cells and fat grafting for treating breast cancer-related lymphedema: Lymphoscintigraphic evaluation with 1 year of follow-up. J Plast Reconstr Aesthet Surg. 2019;72(1):71–7.
Maldonado GE, Perez CA, Covarrubias EE, et al. Autologous stem cells for the treatment of post-mastectomy lymphedema: a pilot study. Cytotherapy. 2011;13(10):1249–55.
Acknowledgments
Dr. Brewster’s data and time on this chapter was supported in part by his research funding from the NIH and VA; NHLBI R01HL143348; VABLRD IO1BX004707; and VARRD I21RX003188. The authors are grateful to the academic support of Emory University’s Department of Surgery, including our leadership, Drs. John F. Sweeney, Grant Carlson, and Will Jordan.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
McLaughlin, D., Cheng, A., Brewster, L. (2021). Stem Cell Therapy for Lymphedema. In: Navarro, T.P., Minchillo Lopes, L.L.N., Dardik, A. (eds) Stem Cell Therapy for Vascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-56954-9_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-56954-9_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-56953-2
Online ISBN: 978-3-030-56954-9
eBook Packages: MedicineMedicine (R0)